0001564590-21-055251.txt : 20211108 0001564590-21-055251.hdr.sgml : 20211108 20211108161245 ACCESSION NUMBER: 0001564590-21-055251 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sana Biotechnology, Inc. CENTRAL INDEX KEY: 0001770121 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39941 FILM NUMBER: 211388078 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUIT 400 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (206) 701-7914 MAIL ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUIT 400 CITY: SEATTLE STATE: WA ZIP: 98102 8-K 1 sana-8k_20211108.htm 8-K sana-8k_20211108.htm
false 0001770121 0001770121 2021-11-08 2021-11-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2021

 

SANA BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Delaware

 

001-39941

 

83-1381173

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

 

(IRS Employer

Identification Number)

188 East Blaine Street, Suite 400

Seattle, Washington 98102

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (206) 701-7914

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

SANA

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


 

 

Item 2.02Results of Operations and Financial Condition.

On November 8, 2021, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release of Sana Biotechnology, Inc. dated November 8, 2021.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

SANA BIOTECHNOLOGY, INC.

 

 

Date: November 8, 2021

By:

/s/ Nathan Hardy

 

 

Nathan Hardy

 

 

Executive Vice President and Chief Financial Officer

 

 

 

EX-99.1 2 sana-ex991_6.htm EX-99.1 sana-ex991_6.htm

 

Exhibit 99.1

Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates

Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs

Q3 2021 cash position of $866.1 million

SEATTLE — November 8, 2021 — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter of 2021.  

“We continue to make progress in building the company, progressing our pipeline, and growing our people and capabilities,” said Steve Harr, Sana’s President and Chief Executive Officer. “The recent licensing of genome editing technology to enable multiple pipeline programs is an example of our continued focus on augmenting our innovative capacity. As our pipeline progresses, we look forward to presenting data from our in vivo CAR T and ex vivo allogeneic CAR T cell programs at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in December.”

Recent Corporate Highlights

 

Announced an agreement for non-exclusive commercial rights to Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs. Engineering cells for therapeutic applications requires technologies for precise editing of their genome sequence. We plan to use the technology with certain product candidates, including many of our allogeneic CAR T and pluripotent stem cell programs.

Third Quarter 2021 Financial Results

GAAP Results

 

Cash Position: Cash, cash equivalents, and marketable securities as of September 30, 2021 were $866.1 million compared to $412.0 million as of December 31, 2020, an increase of $454.1 million. The increase was primarily driven by net proceeds of $626.4 million received in Sana’s initial public offering in February 2021, partially offset by cash used in operations of $141.0 million and cash used for the purchase of property and equipment of $24.7 million.

 

Research and Development Expenses: For the three and nine months ended September 30, 2021, research and development expense, inclusive of non-cash expenses, was $53.2 million and $140.2 million, respectively, compared to $40.1 million and $96.5 million, respectively, for the same periods in 2020. The increases of $13.1 million and $43.6 million, respectively, for the three and nine months ended September 30, 2021 were due to an increase in personnel expenses related to increased headcount to expand Sana’s research and development capabilities, costs for laboratory supplies, costs for preclinical studies and external manufacturing, and facility costs. Research and development expenses include non-cash stock-based compensation of $4.1 million and $9.9 million, respectively, for the three and nine months ended September 30, 2021 and $1.0 million and $2.6 million, respectively, for the same periods in 2020.

 

Research and Development Related Success Payments and Contingent Consideration: For the three and nine months ended September 30, 2021, we recognized non-cash expenses of $16.8 million and $67.8 million, respectively, in connection with the change in the estimated fair value of the success payment liabilities and contingent consideration, compared to $4.5 million and $57.3 million, respectively, for the same periods in 2020.

 

General and Administrative Expenses: General and administrative expenses for the three and nine months ended September 30, 2021, inclusive of non-cash expenses, were $13.4 million and $37.7 million, respectively, compared to $7.1 million and $19.1 million, respectively, for the same periods in 2020. The increases of $6.3 million and $18.6 million, respectively, in the three and nine months ended September 30, 2021 were primarily due to increased personnel-related expenses attributable to an increase in headcount to build our infrastructure, legal fees to support our patent portfolio and license arrangements, insurance associated with being a public company, consulting fees, and facility costs. General and administrative expenses include stock-based compensation of $1.9 million and $5.2 million, respectively, for the three and nine months ended September 30, 2021 and $0.2 million and $0.5 million, respectively, for the same periods in 2020.

 

Net Loss: Net loss for the three and nine months ended September 30, 2021 were $83.3 million, or $0.46 per share, and $245.2 million, or $1.53 per share, respectively, compared to $51.5 million, or $3.76 per share, and $172.1 million, or $14.05 per share, respectively, for the same periods in 2020.

Non-GAAP Measures

 

Non-GAAP Operating Cash Burn: Non-GAAP operating cash burn for the nine months ended September 30, 2021 was $146.4 million compared to $87.2 million for the nine months September 30, 2020. Non-GAAP operating cash burn is the

 


 

 

decrease in cash, cash equivalents, and marketable securities excluding cash inflows from financing activities, cash outflows from business development activities, and the purchase of property and equipment.

 

Non-GAAP Research and Development Expenses: Non-GAAP research and development expenses for the three and nine months ended September 30, 2021 were $53.2 million and $140.1 million, respectively, compared to $31.6 million and $86.5 million, respectively, for the same periods in 2020. Non-GAAP research and development expenses excludes one-time costs to acquire technology.

 

Non-GAAP Net Loss: Non-GAAP net loss for the three and nine months ended September 30, 2021 was $66.5 million, or $0.37 per share, and $177.4 million, or $1.11 per share, respectively, compared to $38.5 million, or $2.81 per share, and $104.9 million, or $8.56 per share, respectively, for the same periods in 2020. Non-GAAP net loss exclude one-time costs to acquire technology and non-cash expenses related to the change in the estimated fair value of contingent consideration and success payment liabilities.

A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

About Sana

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 350 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans; the Company’s participation in the 63rd ASH Annual Meeting and Exposition and the subject matter of the Company’s presentation at that meeting; and the Company’s plans and expectations with respect to the use and utility of Beam’s CRISPR Cas12b nuclease system for Sana’s ex vivo engineered cell programs. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K dated March 24, 2021 and Quarterly Report on Form 10-Q dated November 8, 2021. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

 

###

 

Investor Relations:

Nicole Keith

investor.relations@sana.com

 

Media:

Morgan Warners, Finsbury Glover Hering

media@sana.com

 

 


 

 

Sana Biotechnology, Inc.

Unaudited Selected Consolidated Balance Sheet Data

 

 

 

September 30, 2021

 

 

December 31, 2020

 

 

 

(in thousands)

 

Cash, cash equivalents, and marketable securities

 

$

866,112

 

 

$

411,995

 

Total assets

 

 

1,232,751

 

 

 

730,296

 

Contingent consideration

 

 

131,981

 

 

 

121,901

 

Success payment liabilities

 

 

134,192

 

 

 

76,494

 

Total liabilities

 

 

402,666

 

 

 

298,583

 

Convertible preferred stock

 

 

-

 

 

 

852,897

 

Total stockholders' equity (deficit)

 

 

830,085

 

 

 

(421,184

)

 


 

 

Sana Biotechnology, Inc.

Unaudited Consolidated Statements of Operations

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(in thousands, except per share data)

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

53,245

 

 

$

40,056

 

 

$

140,121

 

 

$

96,453

 

Research and development related success payments and contingent consideration

 

 

16,753

 

 

 

4,489

 

 

 

67,778

 

 

 

57,309

 

General and administrative

 

 

13,433

 

 

 

7,099

 

 

 

37,731

 

 

 

19,063

 

Total operating expenses

 

 

83,431

 

 

 

51,644

 

 

 

245,630

 

 

 

172,825

 

Loss from operations

 

 

(83,431

)

 

 

(51,644

)

 

 

(245,630

)

 

 

(172,825

)

Interest income, net

 

 

158

 

 

 

148

 

 

 

409

 

 

 

622

 

Other income, net

 

 

10

 

 

 

44

 

 

 

24

 

 

 

68

 

Net loss

 

$

(83,263

)

 

$

(51,452

)

 

$

(245,197

)

 

$

(172,135

)

Net loss per common share - basic and diluted

 

$

(0.46

)

 

$

(3.76

)

 

$

(1.53

)

 

$

(14.05

)

Weighted-average number of common shares - basic and diluted

 

 

181,827

 

 

 

13,680

 

 

 

160,515

 

 

 

12,249

 

 


 


 

 

Sana Biotechnology, Inc.

Changes in the Estimated Fair Value of Success Payments and Contingent Consideration

 

 

 

Success Payment

Liability(1)

 

 

Contingent

Consideration(2)

 

 

Total Success Payment Liability and Contingent Consideration

 

 

 

(in thousands)

 

Liability balance as of December 31, 2020

 

$

76,494

 

 

$

121,901

 

 

$

198,395

 

Changes in fair value - expense (gain)

 

 

115,657

 

 

 

11,393

 

 

 

127,050

 

Liability balance as of March 31, 2021

 

 

192,151

 

 

 

133,294

 

 

 

325,445

 

Changes in fair value - expense (gain)

 

 

(83,188

)

 

 

7,163

 

 

 

(76,025

)

Liability balance as of June 30, 2021

 

 

108,963

 

 

 

140,457

 

 

 

249,420

 

Changes in fair value - expense (gain)

 

 

25,229

 

 

 

(8,476

)

 

 

16,753

 

Liability balance as of September 30, 2021

 

$

134,192

 

 

$

131,981

 

 

$

266,173

 

Total change in fair value for the nine months ended September 30, 2021

 

$

57,698

 

 

$

10,080

 

 

$

67,778

 

 

(1)

Cobalt Biomedicine, Inc. (Cobalt) and the Presidents of Harvard College (Harvard) are entitled to success payments pursuant to the terms of their agreements. The success payments are recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations.

(2)

Cobalt is entitled to contingent consideration upon the achievement of certain milestones pursuant to the terms of the agreement. Contingent consideration is recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations.

 

Non-GAAP Financial Measures

To supplement the financial results presented in accordance with generally accepted accounting principles in the United States (GAAP), Sana uses certain non-GAAP financial measures to evaluate its business. Sana’s management believes that these non-GAAP financial measures are helpful in understanding Sana’s financial performance and potential future results, as well as providing comparability to peer companies and period over period. In particular, Sana’s management utilizes non-GAAP operating cash burn, non-GAAP research and development expense and non-GAAP net loss and net loss per share. Sana believes the presentation of these non-GAAP measures provides management and investors greater visibility into the Company’s ongoing actual costs to operate its business, including actual research and development costs unaffected by non-cash valuation changes and one-time expenses for acquiring technology, as well as facilitating a more meaningful comparison of period-to-period activity. Sana excludes these items because they are highly variable from period to period and, in respect of the non-cash expenses, provides investors with insight into the actual cash investment in the development of its therapeutic programs and platform technologies.

These are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Sana’s financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting. Sana’s management uses these supplemental non-GAAP financial measures internally to understand, manage, and evaluate Sana’s business and make operating decisions. In addition, Sana’s management believes that the presentation of these non-GAAP financial measures is useful to investors because they enhance the ability of investors to compare Sana’s results from period to period and allows for greater transparency with respect to key financial metrics Sana uses in making operating decisions. The following are reconciliations of GAAP to non-GAAP financial measures:

 


 

Sana Biotechnology, Inc.

Unaudited Reconciliation of Change in Cash, Cash Equivalents, and Marketable Securities to

Non-GAAP Operating Cash Burn

 

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Beginning cash, cash equivalents, and marketable securities

 

$

411,995

 

 

$

138,982

 

Ending cash, cash equivalents, and marketable securities

 

 

866,112

 

 

 

459,070

 

Change in cash, cash equivalents, and marketable securities

 

 

454,117

 

 

 

320,088

 

Cash paid to purchase property and equipment

 

 

24,660

 

 

 

14,606

 

Change in cash, cash equivalents, and marketable securities, excluding capital expenditures

 

 

478,777

 

 

 

334,694

 

Adjustments:

 

 

 

 

 

 

 

 

Cash paid to acquire technology(1)

 

 

1,246

 

 

 

7,650

 

Cash paid to satisfy contingent liability(2)

 

 

-

 

 

 

6,000

 

Net proceeds received from the initial public offering of common stock

 

 

(626,405

)

 

 

-

 

Net cash received from the sale of convertible preferred stock

 

 

-

 

 

 

(435,538

)

Operating cash burn - Non-GAAP

 

$

(146,382

)

 

$

(87,194

)

 

(1)

The non-GAAP adjustment of $1.2 million for the nine months ended September 30, 2021 was the holdback payment related to the acquisition of Cytocardia, Inc. in November 2019. The non-GAAP adjustment of $7.7 million for the nine months ended September 30, 2020 was the upfront expense related to the acquisition of Oscine Corp. in September 2020.

(2)

The non-GAAP adjustment of $6.0 million for the nine months ended September 30, 2020 was the payment of a contingent liability due to Harvard in connection with the closing of the Series B convertible preferred stock financing.

 


 

Sana Biotechnology, Inc.

Unaudited Reconciliation of GAAP to Non-GAAP Research and Development Expense

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Research and development expense - GAAP

 

$

53,245

 

 

$

40,056

 

 

$

140,121

 

 

$

96,453

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs to acquire technology(1)

 

 

-

 

 

 

(8,500

)

 

 

-

 

 

 

(8,500

)

Change in the estimated fair value of contingent liability(2)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,443

)

Research and development expense - Non-GAAP

 

$

53,245

 

 

$

31,556

 

 

$

140,121

 

 

$

86,510

 

 

(1)

The non-GAAP adjustment of $8.5 million for the three and nine months ended September 30, 2020 was the upfront expense recorded in connection with the acquisition of Oscine Corp. in September 2020.

(2)

The contingent liability was recorded in connection with the Harvard license agreement and paid in June 2020.

 

 


 

 

Sana Biotechnology, Inc.

Unaudited Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss Per Share

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(in thousands, except per share data)

 

Net loss - GAAP

 

$

(83,263

)

 

$

(51,452

)

 

$

(245,197

)

 

$

(172,135

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs to acquire technology(1)

 

 

-

 

 

 

8,500

 

 

 

-

 

 

 

8,500

 

Change in the estimated fair value of the success payment liabilities(2)

 

 

25,229

 

 

 

2,156

 

 

 

57,698

 

 

 

40,637

 

Change in the estimated fair value of contingent consideration(3)

 

 

(8,476

)

 

 

2,333

 

 

 

10,080

 

 

 

16,672

 

Change in the estimated fair value of contingent liability(4)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,443

 

Net loss - Non-GAAP

 

$

(66,510

)

 

$

(38,463

)

 

$

(177,419

)

 

$

(104,883

)

Net loss per share - GAAP

 

$

(0.46

)

 

$

(3.76

)

 

$

(1.53

)

 

$

(14.05

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs to acquire technology(1)

 

 

-

 

 

 

0.62

 

 

 

-

 

 

 

0.69

 

Change in the estimated fair value of the success payment liabilities(2)

 

 

0.14

 

 

 

0.16

 

 

 

0.36

 

 

 

3.32

 

Change in the estimated fair value of contingent consideration(3)

 

 

(0.05

)

 

 

0.17

 

 

 

0.06

 

 

 

1.36

 

Change in the estimated fair value of contingent liability(4)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

0.12

 

Net loss per share - Non-GAAP

 

$

(0.37

)

 

$

(2.81

)

 

$

(1.11

)

 

$

(8.56

)

Weighted-average shares outstanding - basic

 

 

181,827

 

 

 

13,680

 

 

 

160,515

 

 

 

12,249

 

 

(1)

The cost to acquire technology of $8.5 million was the upfront expense recorded in connection with the acquisition of Oscine Corp. in September 2020.

(2)

For the three and nine months ended September 30, 2021, the expenses related to the Cobalt success payment liability were $21.8 million and $46.9 million, respectively, and $1.3 million and $35.2 million, respectively, for the same periods in 2020. For the three and nine months ended September 30, 2021 the expenses related to the Harvard success payment liability were $3.4 million and $10.8 million, respectively, and $0.8 million and $5.5 million, respectively, for the same periods in 2020. The increase in expense for the Cobalt and Harvard success payments for the three and nine months ended September 30, 2021 were due to changes in our market capitalization and common stock price during the relative periods.

(3)

The contingent consideration was recorded in connection with the acquisition of Cobalt. The change in value of the contingent consideration was primarily due to scientific progress toward the achievement of milestones during the relative periods. In addition, the discount rate used in the calculation increased, which contributed to the decline in value for the three months ended September 30, 2021.

(4)

The contingent liability was recorded in connection with the Harvard license agreement and paid in June 2020.

 

 

EX-101.SCH 3 sana-20211108.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 sana-20211108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 sana-20211108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 sana-8k_20211108_htm.xml IDEA: XBRL DOCUMENT 0001770121 2021-11-08 2021-11-08 false 0001770121 8-K 2021-11-08 SANA BIOTECHNOLOGY, INC. DE 001-39941 83-1381173 188 East Blaine Street Suite 400 Seattle WA 98102 206 701-7914 false false false false Common Stock, $0.0001 par value per share SANA NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 08, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2021
Entity Registrant Name SANA BIOTECHNOLOGY, INC.
Entity Central Index Key 0001770121
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-39941
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 83-1381173
Entity Address, Address Line One 188 East Blaine Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98102
City Area Code 206
Local Phone Number 701-7914
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol SANA
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sana-8k_20211108.htm sana-20211108.xsd sana-20211108_lab.xml sana-20211108_pre.xml sana-ex991_6.htm http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sana-8k_20211108.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sana-8k_20211108.htm" ] }, "labelLink": { "local": [ "sana-20211108_lab.xml" ] }, "presentationLink": { "local": [ "sana-20211108_pre.xml" ] }, "schema": { "local": [ "sana-20211108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sana", "nsuri": "http://sana.com/20211108", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "sana-8k_20211108.htm", "contextRef": "C_0001770121_20211108_20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "sana-8k_20211108.htm", "contextRef": "C_0001770121_20211108_20211108", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sana.com/20211108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-21-055251-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-055251-xbrl.zip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end